CN111821393A - Application and preparation method of composition for improving blood fat, fatty liver, fatty hepatitis and blood sugar regulation - Google Patents
Application and preparation method of composition for improving blood fat, fatty liver, fatty hepatitis and blood sugar regulation Download PDFInfo
- Publication number
- CN111821393A CN111821393A CN201910444188.1A CN201910444188A CN111821393A CN 111821393 A CN111821393 A CN 111821393A CN 201910444188 A CN201910444188 A CN 201910444188A CN 111821393 A CN111821393 A CN 111821393A
- Authority
- CN
- China
- Prior art keywords
- coix seed
- extract
- subject
- composition
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 40
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 29
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 28
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 title claims description 39
- 208000006454 hepatitis Diseases 0.000 title claims description 17
- 231100000283 hepatitis Toxicity 0.000 title claims description 15
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 127
- 239000000284 extract Substances 0.000 claims abstract description 109
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 239000008103 glucose Substances 0.000 claims description 20
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims description 15
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 13
- 238000002137 ultrasound extraction Methods 0.000 claims description 13
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 108090000340 Transaminases Proteins 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 6
- 230000002440 hepatic effect Effects 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000006286 aqueous extract Substances 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 5
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 4
- 241000209205 Coix Species 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 102000003929 Transaminases Human genes 0.000 claims 2
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 18
- 235000009200 high fat diet Nutrition 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 102000014898 transaminase activity proteins Human genes 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 3
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 238000012742 biochemical analysis Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000849 liver cell damage Toxicity 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000008425 Coix lacryma jobi var lacryma jobi Nutrition 0.000 description 1
- 240000000576 Coix lacryma jobi var. lacryma jobi Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Botany (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a coix seed extract for improving blood fat, fatty liver inflammation and blood sugar regulation, an application and a preparation method thereof. The invention also provides a product produced by the method, which can effectively prevent or improve fatty liver and/or fatty liver inflammation and regulate blood sugar.
Description
Technical Field
The invention provides a coix seed extract capable of improving blood fat, fatty liver inflammation and blood sugar regulation, a related composition thereof, a preparation method of the composition and application of the composition.
Background
Liver diseases caused by obesity and insulin imbalance have become a global health problem that has not been ignored in recent years. Fatty liver is the initial stage of non-alcoholic fatty liver disease and is a common metabolic symptom, namely caused by an imbalance of lipid metabolism. At present, a lot of clinical data show that "fatty liver" also goes through the process of "cirrhosis", and symptoms of steatohepatitis and hepatic necrosis occur.
In view of the above, how to develop extracts or compositions derived from plant functional materials or preparations to help lower blood sugar, lower blood lipid, prevent fatty liver and fatty liver inflammation, and alleviate chronic inflammation, especially, the extracts of food materials are used to solve the deficiencies of the prior art, and thus, there is a need for solving the problems in the related art.
Disclosure of Invention
Therefore, the invention aims to solve the prior technical problems that no specific medicine, natural product or extract is available at present and can improve fatty liver and hepatitis and regulate and control blood sugar and blood fat.
The present invention provides a use of an extract of Coix seed for preparing a composition for improving hepatitis and regulating blood sugar, wherein the composition comprises an extract of Coix seed (Coix lacryma-jobi) and an active ingredient thereof, the extract of Coix seed is selected from a water extract of Coix seed (Coix lacryma-jobi) or a water extract of Coix seed (Coix lacryma-jobi), and the composition is administered to a subject in an effective amount.
The invention provides a use of a composition for improving blood fat, fatty liver, fatty hepatitis and blood sugar regulation, wherein the composition consists of Coix seed (Coix lacryma-jobi) extract and active ingredients thereof, the Coix seed extract is selected from Coix seed (Coix lacryma-jobi) water extract or Coix seed (Coix lacryma-jobi) wine water extract, and the composition is administered to a required individual in effective dose.
The invention provides a use of a composition in the preparation of a medicament or/and food or/and dietary supplement for improving blood fat, fatty liver, fatty hepatitis and blood sugar regulation, wherein the composition is composed of Coix seed (Coix lacryma-jobi) extract and active ingredients thereof, the Coix seed extract is selected from Coix seed (Coix lacryma-jobi) water extract or Coix seed (Coix lacryma-jobi) wine water extract, and the composition is administered to a required individual in an effective dose.
In one embodiment of the present invention, the administration comprises oral administration.
In the embodiment of the present invention as described above, the effective dose of the composition for each administration to a subject in need thereof is 750 to 2250 mg/kg of body weight, wherein the content of the coix seed extract is 0.05 to 5% by weight.
In one embodiment of the present invention, the desired subject is selected from one or more of healthy subject, hyperlipidemic subject, hepatitis subject, fatty liver subject, or hyperglycemic subject.
In the embodiments of the present invention as described above, the composition has the effects of improving glucose tolerance in the desired subject, and reducing the fasting blood glucose level in the desired subject.
Preferably, the fatty liver subject further includes a non-alcoholic fatty liver subject.
Preferably, the hepatitis subjects further include steatohepatitis subjects and nonalcoholic steatohepatitis subjects.
In embodiments of the invention as described above, the composition has the efficacy of reducing the bran oxalate transaminase (AST) index, bran pyruvate transaminase (ALT) index.
In one embodiment of the invention, the composition has the efficacy of lowering plasma Total Cholesterol (TC) values, lowering low density lipoprotein cholesterol (LDL-C) values.
In one embodiment of the invention, the composition has the efficacy of treating or/and preventing fatty liver (Steatosis) and Steatohepatitis (Steatohepatitis).
Preferably, the composition has the effects of effectively reducing triglyceride (i.e. triglyceride) of liver by 14-18%, reducing liver fat accumulation and improving fatty liver symptoms.
The subsidiary technical means derived from the necessary technical means is that the composition further comprises a pharmaceutically acceptable carrier, and the composition is used for preparing medicines, dietary supplements, foods and health-care foods.
In the embodiment of the present invention as described above, the coix seed extract is obtained by performing ultrasonic assisted extraction on the extract to obtain the composition.
In an embodiment of the present invention, the ultrasonic-assisted extraction is selected from pulsed ultrasonic-assisted extraction or continuous oscillation ultrasonic-assisted extraction.
Preferably, the power of the ultrasonic-assisted extraction is 50W-800W, the temperature is 20 ℃ to 80 ℃, and the time is 5 seconds to 60 minutes.
Preferably, the coix seed extract is obtained by extracting coix seeds and extract liquor according to the proportion of 1: 3-1: 20.
The subsidiary technical means derived from the necessary technical means is that the coix seed extract is obtained by extracting by taking water as an extraction liquid.
The subsidiary technical means derived from the necessary technical means is that the coix seed extract is obtained by extracting diluted alcohol serving as an extraction liquid, wherein the volume ratio of alcohol to water in the diluted alcohol extraction liquid is 1-99: 99 to 1.
Drawings
FIG. 1 is a graph of animal body weight change in accordance with an embodiment of the present invention.
Figure 2 is a graph of the effective use rate of food fed to an animal according to an embodiment of the present invention.
Figure 3 is a fat weight map of an embodiment of the invention.
Fig. 4 is a liver weight measurement chart of an embodiment of the present invention.
FIG. 5 shows liver Triglyceride (TG) values of examples of the present invention.
FIG. 6 shows the cholesterol (cholestrol) values of the liver in the example of the present invention.
Figure 7 shows plasma glutamate transaminase (GOT) values in accordance with an embodiment of the present invention.
Figure 8 shows plasma Glutamate Pyruvate Transaminase (GPT) values in accordance with an embodiment of the present invention.
FIG. 9 is a chart showing the staining of liver with hematoxylin-eosin according to an embodiment of the present invention.
FIG. 10 is a chart showing the staining of the fat hematoxylin-eosin according to the example of the present invention.
FIG. 11 is a graph showing plasma Triglyceride (TG) values of examples of the present invention.
FIG. 12 is a graph showing Total Cholesterol (TC) values in plasma in accordance with an example of the present invention.
FIG. 13 is a graph showing plasma high density lipoprotein cholesterol (HDL-C) values in examples of the present invention.
FIG. 14 is a graph showing plasma low density lipoprotein cholesterol (LDL-C) values in examples of the present invention.
FIG. 15 is a graph showing a glucose tolerance test in the examples of the present invention.
Fig. 16 is a graph showing the variation in blood glucose levels when an individual is administered a coix seed extract in accordance with an embodiment of the present invention.
FIG. 17 is a graph of plasma urea nitrogen (BUN) values for an example of the present invention.
FIG. 18 shows plasma Creatinine (Creatinine) values in examples of the present invention.
Detailed Description
The present invention is described in terms of specific embodiments, which will become apparent to those skilled in the art from this disclosure. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways.
In one embodiment of the present invention, the coix seed is selected from, but not limited to, red coix seed, white coix seed and large coix seed, wherein the red coix seed is obtained by removing the coix seed shell, and the white coix seed is obtained by removing the bran from the red coix seed. Further, the aforementioned variety of Coix seed may be selected from, but not limited to, large seed Coix seed (Coix lacryma-jobi var. lacryma-jobi, var. major), horse-aided seed Coix seed (Coix lacryma-jobi var. ma-yuan), No. 1 in Coix seed table, No. 2 in Coix seed table, No. 3 in Coix seed table, No. 4 in Coix seed table, No. 5 in Coix seed table.
In one embodiment of the present invention, the composition may comprise a coix seed water extract or a coix seed wine water extract. In another embodiment of the present invention, the alcohol-water extract may be called diluted alcohol extract, wherein the volume ratio of alcohol to water in the alcohol-water extract is in the range of 1-99: 99 to 1, that is, the volume ratio of alcohol to water is in the range of 1 to 99: 99 to 1. Further, the water extract and the alcohol water extract may be subjected to ultrasonic-assisted extraction (UAE). In another embodiment of the present invention, the active ingredient is selected from the group consisting of polysaccharides, medium and low polarity ingredients.
Furthermore, in another embodiment of the present invention, the ultrasonic-assisted extraction can be performed by pulse or continuous oscillation. For example, the power of the ultrasonic oscillation is 50W-800W, the temperature is 20 deg.C-80 deg.C, the time is 5 seconds-60 minutes, and the ratio of the coix seed to the extraction liquid is 1: 3-1: 20.
In one embodiment of the present invention, the composition may include a pharmaceutically acceptable carrier, adjuvant, or excipient; in another embodiment of the present invention, the composition can be used for preparing a medicine, a dietary supplement, a food, a health food.
The term "pharmaceutically acceptable carrier" as used herein refers to a pharmaceutical composition that is mixed with a pharmaceutically acceptable carrier, which is well known in the art, in accordance with conventional pharmaceutical compounding techniques, for the purposes of facilitating the pharmaceutical dosage process, or for different dosage forms of administration, and such carriers are available in a wide variety of forms. The prescription of certain pharmaceutically acceptable carriers can be found in The handbook of Pharmaceutical Excipients (The Hand Book of Pharmaceutical Excipients) published by The American medical Association and The Pharmaceutical Society of Great Britain. For example, tablets, capsules, gels, solutions or suspensions may also comprise the following ingredients: a pharmaceutically acceptable excipient or carrier which is non-toxic, inert solid or semi-solid, diluent, encapsulating material, gel base or formulation adjuvant in any form, for example: microcrystalline cellulose (Microcrystalline cellulose), glucose, lactose, skim milk powder, starch, dextrin, cyclodextrin, silica, anhydrous calcium hydrogen phosphate, magnesium phosphate, stearic acid, magnesium stearate, or artificial perfume. On the other hand, the extract can be combined with other foods or drinks to be orally taken by a living body in a state suitable for eating.
Furthermore, the term "subject" as used herein is intended to include, by way of example and not limitation, humans, cows, pigs, horses, sheep, dogs, mice, rats, rabbits, and birds, such as chickens, ducks, geese, and turkeys. Of course, the present invention is not limited thereto, and in another embodiment of the present invention, the subject is selected from healthy subjects, hyperlipidemic subjects, hepatitis subjects, fatty liver subjects, and hyperglycemic subjects. Further, the fatty liver individual further comprises a non-alcoholic fatty liver individual, wherein the hepatitis individual further comprises a steatohepatitis individual, a non-alcoholic fatty hepatitis individual
Of course, the present invention is not limited thereto, and the "effective dose" refers to an amount of the effective effect of promoting improvement of fatty liver, especially improvement of symptoms of nonalcoholic fatty liver disease (Steatohepatitis/NAFLD), improvement of hepatitis, especially improvement of symptoms of Steatohepatitis (Steatohepatitis), symptoms of nonalcoholic Steatohepatitis (Hapatitis/NASH), significant reduction of Total Cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) values in plasma, reduction of the transaminase of oxalate (AST) index and transaminase of pyruvate (ALT) index, significant improvement of blood glucose regulation, improvement of hepatocyte damage and maintenance of hepatocyte and hepatocyte nuclear integrity in a manner of oral administration, injection, intranasal administration, inhalation, topical administration or transdermal administration. In another embodiment of the present invention, the effective amount of the coix seed extract can be selected from 0.01% of coix seed extract, 0.03% of coix seed extract, 0.05% of coix seed extract, 0.07% of coix seed extract, 0.09% of coix seed extract, 0.1% of coix seed extract, 0.3% of coix seed extract, 0.5% of coix seed extract, 0.7% of coix seed extract, 0.9% of coix seed extract, 1% of coix seed extract, 3% of coix seed extract, 5% of coix seed extract, 7% of coix seed extract, 9% of coix seed extract, 11% of coix seed extract, 13% of coix seed extract, 15% of coix seed extract, 17% of coix seed extract, 19% of coix seed extract, 21% of coix seed extract, 23% of coix seed extract and 25% of coix seed extract. Wherein 1% of the coix seed extract can be obtained by wine-water extraction, and 3% of the coix seed extract can be obtained by water extraction.
Examples
Example one animal model of high fat diet mice
The experimental animals were selected from C57BL/6 male mice, age 4 weeks, purchased from Lescow, Inc. (Taiwan, China). Wherein the experimental Animals are nursed and cared according to the American Guide for the Care and use of laboratory Animals and the national Animal protection law (Animal Welfare Act). After 1 week acclimatization and food, the mice were randomly divided into a control group, a control group and at least one test group, wherein the number of mice in each group was 8 or more and the animal diet calorie of high fat diet was as shown in table one. Animal feeds can be divided into normal diet (NCD) feeds and High Fat Diet (HFD) feeds. Mice are fed with a high dose (e.g., 3%) and a low dose (e.g., 1%) of the coix seed extract mixed with a normal diet (NCD) diet (i.e., 1% coix seed extract mixed diet) and a High Fat Diet (HFD) diet (i.e., 3% coix seed extract mixed diet), respectively. Wherein the dosage of the coix seed extract applied to a mouse per time is 750-2250 mg/kg body weight. In other words, the dose of coix seed extract administered to the mice is about 0.05% to about 5% by weight. Mice were fed the aforementioned diet for 8-12 weeks in this animal mode. Food consumption and weight gain will be measured weekly, respectively. All mice were fasted for 18 hours and subjected to the glucose tolerance test (IPGTT) 2 days before sacrifice.
Animal feed calories for high fat diets
Example two animal body weight Change and food effective use Rate (FER)
Referring to fig. 1, in one embodiment of the present invention, mice of different groups were fed with normal diet (NCD; WT) feed, High Fat Diet (HFD) feed, mixed feed of 1% of coix seed extract and mixed feed of 3% of coix seed extract, wherein 1% of coix seed extract was wine-extracted and 3% of coix seed extract was water-extracted. Wherein the body weight of the mouse is measured and recorded by an electronic scale from 0 week (W0) to 10 weeks (W10). Furthermore, the food consumption of the mice of the different groups (as shown in FIG. 2) can be measured by an electronic scale.
EXAMPLE III fat weight and liver weight changes in animal subjects administered Coix seed extract
Referring to fig. 3 and 4, after the mice in the different groups are sacrificed, the fat weight (see fig. 3) and the liver weight (see fig. 4) can be directly measured by using an electronic scale.
EXAMPLE four Biochemical analysis of hepatic triglyceride (hepatic triglyceride) and Cholesterol administered to animal subjects with Coix seed extract
As shown in fig. 5 and 6, after feeding the mice with the coix seed extract, the mice were able to effectively reduce hepatic triglyceride (triglyceride) by 14% to 18% (as shown in fig. 5, wherein "×" represents a very significant reduction P <0.01), wherein the hepatic triglyceride of the animals fed with the 3% coix seed extract mixed feed group was significantly reduced compared with the other groups. The liver cholesterol (cholestrol) values of the individual mice of the different groups are shown in FIG. 6.
Example five fatty inflammation index of liver
Referring to fig. 7 and 8, in one embodiment of the present invention, liver fat inflammation index of mice in different groups fed with different animal feeds can be measured by measuring the values of glutamic oxaloacetic transaminase (also called glutamic oxaloacetic transaminase, GOT or AST) in the plasma of mice (see fig. 7, wherein "," "means" significantly reduced level, which respectively reaches P <0.05 and 0.01 level) and glutamic pyruvic transaminase (also called glutamic pyruvic transaminase, GPT or ALT) (see fig. 8, wherein "" means "significantly reduced level, which is P < 0.05). Wherein, the mice fed the coix seed water extract and/or coix seed wine water extract can remarkably improve the hepatitis phenomenon caused by feeding high fat feed, and reduce the bran oxalate transaminase (AST) index and the bran pyruvate transaminase (ALT) index.
Example six Hematoxylin-eosin staining of liver and adipose tissue (Hematoxylin and eosin staining)
Referring to fig. 9 and 10, in one embodiment of the present invention, after sacrifice, the liver and adipose tissue of different groups are taken out and soaked in 4% paraformaldehyde for fixation, and then paraffin embedding and sectioning are performed, and the liver tissue type is further stained with hematoxylin-eosin (H & E) (as shown in fig. 9). Wherein FIG. 9A is a photograph of a liver tissue section of a mouse fed with a normal diet (NCD; WT) feed group. FIG. 9B is a sectional view of liver tissue of mice fed a High Fat Diet (HFD), in which the pathological manifestations of liver cell disease, including fat accumulation, irregular cell enlargement and wrinkles, nuclear enlargement, air bubbles, etc. are observed when the mice are fed a high fat diet. Fig. 9C is a photograph of a liver tissue section of a mouse fed with an animal feed containing an alcoholic extract of the present invention that does not reduce oil droplet accumulation but maintains healthy hepatocytes. Fig. 9D is a sectional view of liver tissue of a mouse fed with an animal feed containing an aqueous extract of the present invention, showing that the aqueous extract not only reduces the accumulation of oil droplets, but also maintains the healthy and normal liver cell morphology. In other words, the animals suffered from fatty liver and liver cell damage due to high-fat feed, and the cell and cell nucleus integrity was maintained by feeding the wine extract of whole grain coix seed and/or the water extract of coix seed according to the present invention.
In summary, the biological individual can effectively reduce the accumulation of liver fat and improve the symptoms of fatty liver by taking the coix seed water extract and/or coix seed wine water extract.
In addition, FIG. 10A is a sectional view of mouse adipose tissues in a normal diet (NCD; WT) group. Fig. 10B is a sectional view of adipose tissues of mice in the High Fat Diet (HFD) group. Fig. 10C is a section of mouse adipose tissue from the 1% coix seed extract group. Fig. 10D is a section of mouse adipose tissue from the 3% coix seed extract group.
EXAMPLE seventhly, Biochemical analysis of serum
Referring to FIGS. 11-14, biochemical analysis of serum from mice was performed by measuring Triglyceride (TG) value (shown in FIG. 11), Total Cholesterol (TC) value (shown in FIG. 12, wherein "," "represents the degree of reduction of P <0.05, a significant level of 0.01), high density lipoprotein cholesterol (HDL-C) value (shown in FIG. 13), and low density lipoprotein cholesterol (LDL-C) value (shown in FIG. 14, wherein" "represents the degree of reduction of P <0.05, a statistically significant difference of P <0.01) using biochemical test strips with FUJI DRI-CHEM biochemical analyzer. Wherein, the wine extract of the whole grain coix seed has the functions of improving the symptom of hyperlipidemia caused by feeding high-fat feed, and obviously reducing the Total Cholesterol (TC) value and the low-density lipoprotein cholesterol (LDL-C) value of blood plasma.
EXAMPLE eight glucose tolerance test
Figure 15, IPGTT intraperitoneal glucose tolerance test. Mice were given glucose solution injections (3g/kg body weight) followed by fasting overnight and mouse blood glucose measurements at 0, 30, 60, 90 and 120 min using and then New Biotech (Bioptik Technology, Inc) such as the Ready to test blood glucose machine. Where AUC represents the area under the blood glucose concentration-time curve (area under curve). Mice fed the coix seed water extract and/or coix seed wine water extract can remarkably improve the phenomenon of poor blood sugar regulation and/or hyperglycemia (hyperglycemic) caused by feeding high-fat feed.
EXAMPLE ninth blood glucose Change in an individual taking Coix seed extract
Referring to fig. 16, the blood glucose change values of the coix seed extract were measured. In one embodiment of the present invention, mice of different groups were fed with normal diet (NCD; WT) feed, High Fat Diet (HFD) feed, mixed feed of 1% of coix seed extract and mixed feed of 3% of coix seed extract, and blood glucose levels of the mice were measured and recorded from week 0 (W0) to week 10 (W10). Compared with the mice fed with the mixed feed containing 1% of coix seed extract and 3% of coix seed extract, the mice fed with the mixed feed containing 1% of coix seed extract and 3% of coix seed extract have the tendency of reducing the blood sugar value of the mice from 4 weeks (W4) until the mice sacrifice the animals at 10 weeks, which shows that the coix seed extract disclosed by the invention can stabilize the blood sugar value of the animals for a long time and has statistically significant difference.
In summary, the biological individuals can effectively improve the glucose tolerance and the fasting blood glucose value by taking the coix seed water extract and/or the coix seed wine water extract of the invention (as shown in fig. 15 and 16).
EXAMPLE ten Kidney safety analysis
Referring to FIGS. 17 and 18, the kidney safety analysis of mice was performed by measuring the plasma urea nitrogen (BUN) value (shown in FIG. 17) and the Creatinine (Creatinine) value (shown in FIG. 18) using the chip test strip with the FUJI DRI-CHEM biochemical analyzer.
In other words, the efficacy of the coix seed extract of the present invention obtained by the above-mentioned examples is shown in table two.
Second, efficacy of Job's tears seed extract
In conclusion, the coix seed extract of the invention has the effects of improving blood fat, improving symptoms of nonalcoholic fatty liver disease (Steatohepatis/NAFLD), improving liver inflammation, particularly improving symptoms of Steatohepatitis (Steatohepatis) and nonalcoholic fatty liver inflammation (Hapatitis/NASH), remarkably reducing Total Cholesterol (TC) value and low-density lipoprotein cholesterol (LDL-C) value of blood plasma, reducing oxalate transaminase (AST) index and glutamic-pyruvic transaminase (ALT) index, remarkably improving blood glucose regulation, effectively improving glucose tolerance and fasting blood glucose value, improving liver cell damage, maintaining integrity of liver cells and the like.
In other words, the coix seed extract of the invention can simultaneously improve fatty liver, liver inflammation, blood fat and blood sugar regulation and control functions.
The foregoing embodiments are merely illustrative of the principles and effects of the present invention, which is not intended to limit the invention so as to enable those skilled in the art to understand the invention and practice the invention accordingly. Accordingly, equivalent modifications, adaptations, and variations of the above-described embodiments may occur to one skilled in the art without departing from the spirit of the invention. The scope of the invention is to be determined by the following claims.
Claims (18)
1. Use of a composition for improving blood lipids, fatty liver, steatohepatitis and blood glucose regulation, wherein the composition consists of an extract of Coix seed (Coix lacryma-jobi) and an active ingredient thereof, wherein the extract of Coix seed is selected from an aqueous extract of Coix seed (Coix lacryma-jobi) or an aqueous extract of Coix seed (Coix lacryma-jobi), and wherein the composition is administered to a subject in need thereof in an effective amount.
2. The use of claim 1, wherein said administration comprises oral administration.
3. The use of claim 2, wherein the effective dose of the composition is 750-2250 mg/kg body weight per administration of the desired subject, wherein the extract of Job's tears is 0.05-5% by weight.
4. The use of claim 3, wherein the subject in need thereof is a healthy subject, a hyperlipidemic subject, a hepatitis subject, a fatty liver subject, or a hyperglycemic subject.
5. The use of claim 4, wherein said composition has the effect of improving glucose tolerance in said subject in need thereof, and reducing fasting blood glucose levels in said subject in need thereof.
6. The use of claim 4, wherein the fatty liver subject further comprises a non-alcoholic fatty liver subject.
7. The use of claim 4, wherein the hepatitis subject further comprises a steatohepatitis subject, or/and a nonalcoholic steatohepatitis subject.
8. Use according to claim 4, characterized in that the composition has the effect of lowering the bran oxalate transaminase index, the bran pyruvate transaminase index.
9. Use according to claim 6, 7 or 8, characterized in that said composition has the effect of reducing the plasma total cholesterol value, the low density lipoprotein cholesterol value.
10. The use according to claim 6, 7 or 8, wherein the composition has the efficacy of preventing fatty liver and steatohepatitis.
11. Use according to claim 6, 7 or 8, characterized in that the composition has the effect of reducing hepatic triglycerides by 14-18%, reducing hepatic fat accumulation, ameliorating fatty liver symptoms.
12. The use according to claim 1, further comprising a pharmaceutically acceptable carrier, wherein the composition is used for the preparation of a pharmaceutical, dietary supplement, food or nutraceutical product.
13. The use according to claim 1, wherein said extract of coix seed of said composition is obtained by ultrasonic assisted extraction.
14. The use according to claim 13, wherein the ultrasound-assisted extraction is selected from pulsed ultrasound-assisted extraction or continuous-oscillation ultrasound-assisted extraction.
15. The use according to claim 14, wherein the power of the ultrasonic-assisted extraction is 50W to 800W, the temperature is 20 ℃ to 80 ℃, and the time is 5 seconds to 60 minutes.
16. The use as claimed in claim 15, wherein the extract of coix seed is obtained by extracting coix seed and extract in a ratio of 1:3 to 1: 20.
17. The use as claimed in claim 16, wherein the extract of coix seed is obtained by extraction with an aqueous extract.
18. The use as claimed in claim 16, wherein the extract of coix seed is obtained by extracting with a diluted alcohol extract, wherein the volume ratio of alcohol to water in the diluted alcohol extract is in the range of 1-99: 99 to 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW108113863 | 2019-04-19 | ||
| TW108113863A TW202038989A (en) | 2019-04-19 | 2019-04-19 | Compositions for improving hyperlipidemia, steatosis, steatohepatitis and glycemic control and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111821393A true CN111821393A (en) | 2020-10-27 |
Family
ID=72911555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910444188.1A Pending CN111821393A (en) | 2019-04-19 | 2019-05-27 | Application and preparation method of composition for improving blood fat, fatty liver, fatty hepatitis and blood sugar regulation |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111821393A (en) |
| TW (1) | TW202038989A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778380A (en) * | 2004-11-23 | 2006-05-31 | 乔志亚生技股份有限公司 | Extraction of Job's tears seeds, its component and curative effect |
| TW200821380A (en) * | 2006-11-15 | 2008-05-16 | Jojia Bio Tech Co Ltd | Adlay oil capable of reducing blood fat and low density cholesterol and the concentrating method of the same |
-
2019
- 2019-04-19 TW TW108113863A patent/TW202038989A/en unknown
- 2019-05-27 CN CN201910444188.1A patent/CN111821393A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778380A (en) * | 2004-11-23 | 2006-05-31 | 乔志亚生技股份有限公司 | Extraction of Job's tears seeds, its component and curative effect |
| TW200821380A (en) * | 2006-11-15 | 2008-05-16 | Jojia Bio Tech Co Ltd | Adlay oil capable of reducing blood fat and low density cholesterol and the concentrating method of the same |
Non-Patent Citations (2)
| Title |
|---|
| 吴映梅: "薏苡仁的药理活性及其应用的研究进展", 《农产品加工》 * |
| 张建民等: "薏苡仁提取物改善大鼠非酒精性脂肪肝游离脂肪酸的代谢机制研究", 《中国药师》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202038989A (en) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN104304679B (en) | A kind of B B-complex C, E immune polysaccharide microemulsion preparation and its preparation method and application | |
| US11612629B2 (en) | Pharmaceutical composition for preventing or treating muscle diseases, containing ginseng berry extract as active ingredient | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN114632101A (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes as well as preparation method and application thereof | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN111821393A (en) | Application and preparation method of composition for improving blood fat, fatty liver, fatty hepatitis and blood sugar regulation | |
| CN109316565B (en) | Blood fat reducing composition and preparation method and application thereof | |
| KR20190003092A (en) | Composition for preventing, improving or treating stress and depression comprising medicinal herb complex extract as effective component | |
| TW201507725A (en) | The uses of hydroxyl polymethoxylflavones and/or derivative thereof | |
| Bazekin et al. | The Effect of new immunostimulants of tissue and plant origin on the morphological characteristics of the immune system’s central organs and the dynamics of serum immunoglobulins | |
| CN102335347A (en) | Panax pseudo-ginseng and panax quinquefolium soft capsules | |
| CN114588216A (en) | Pharmaceutical composition with blood fat reducing effect and preparation method and application thereof | |
| CN110038090A (en) | A kind of compound celery oil self-emulsifying soft capsule and preparation method thereof with antigout effect | |
| CN113712982B (en) | Composition for preventing or treating non-alcoholic fatty liver disease and obesity, and preparation method and application thereof | |
| CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
| TWI825706B (en) | Lactobacillus paracasei fermented turmeric for mediating metabolic diseases | |
| CN116251117B (en) | Rhodiola rosea compound preparation for preventing and treating acute altitude sickness and preparation method thereof | |
| CN115317534B (en) | Application of myrtle extract in reducing blood sugar and treating diabetic nephropathy | |
| KR20120121232A (en) | Preparation method of extract of Picrasma quassioides and use of the extracts | |
| CN108201602A (en) | A kind of Chinese medicine composition for having effects that assist reducing blood lipid and/or protect blood vessel and preparation method thereof and product | |
| KR20230038355A (en) | Composition for preventing, treating, or alleviating obesity or obesity-related disease comprising Setaria viridis extracts as an active ingredient | |
| CN100402064C (en) | Liver-protecting sobering-up capsule and method for preparing the same by utilizing grape peel | |
| CN117695296A (en) | Application of organic selenium compound in preventing or treating metabolic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201027 |